Progress in novel monoclonal antibodies in the treatment of diffuse large B-cell lymphoma

Abstract:

Diffuse large B-cell lymphoma（DLBCL） is an aggressive lymphoma usually treated with CD20 monoclonal antibodies （mAb），rituximab in combination with chemotherapy. However，there are still some relapsed/refractory（R/R） patients who cannot be cured. In recent years，many novel monoclonal antibodies have been developed to treat DLBCL，which has significantly improved the prognosis of R/R DLBCL. In this review，we systematically discuss these mAb，including traditional mAb，bispecific antibodies （bsAb），and antibody-drug conjugates（ADCs）. Firstly，other traditional mAb rather than rituximab are introduced in this review， mainly involving the improvement of monoclonal antibody structure and targeting more targets. Then，we elaborate the basic structure and mechanism of bsAb，as well as various possibilities brought by various combination from different binding sites. Finally，the mechanism and structure of ADCs are analyzed and compared in detail. The article also reviews the latest clinical trial data of these antibodies in treatment of DLBCL，including response rates，progression-free survival and other efficacy results，as well as major adverse reactions.